sb-334867-a and Bulimia

The orexin (OX) system has been implicated in food-reinforced behavior, food-seeking and food overconsumption. Recent evidence suggests that OX signaling might influence consumption of palatable foods with high reinforcing value depending upon the caloric status of the animal. The present study evaluates from a pharmacological and a molecular approach the contribution of OX to excessive binge-like consumption of highly preferred palatable substances (sucrose and saccharin) in ad libitum-fed C57BL/6J mice. The main findings of this study are: (1) intraperitoneal (ip) injection of SB-334867 (10, 20 or 30mg/kg), a selective OXR1 antagonist, significantly decreased binge-like consumption of sucrose (10%, w/v) and saccharin (0.15%, w/v) during the test day in a Drinking in the Dark procedure in ad libitum-fed animals, without evidence of any significant alteration of locomotor activity. (2) Four repetitive, 2-h daily episodes of sucrose and saccharin (but not water) binge-like drinking significantly dampened OX mRNA expression in the LH. Present findings show for the first time a role for OXR1 signaling in binge-like consumption of palatable substances in animals under no caloric needs. Targeting OXR1 could represent a novel pharmacological approach to treat binge-eating episodes.

Topics: Animals; Benzoxazoles; Bulimia; Dietary Sucrose; Dose-Response Relationship, Drug; Drinking Behavior; Drinking Water; Energy Intake; Hypothalamic Area, Lateral; Intracellular Signaling Peptides and Proteins; Male; Mice, Inbred C57BL; Mitochondrial Proteins; Motor Activity; Naphthyridines; Neuropeptides; Neurotransmitter Agents; Nuclear Proteins; Orexins; RNA, Messenger; Saccharin; Urea